Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Jiangsu HengRui Medicine Co., Ltd.
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Taiho Oncology, Inc.
NRG Oncology
Merck Sharp & Dohme LLC
PrECOG, LLC.
Eli Lilly and Company
University of Vermont
Eli Lilly and Company
Boehringer Ingelheim
Gilead Sciences
Eli Lilly and Company
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Pfizer
University of Maryland, Baltimore
Wake Forest University Health Sciences
University Medical Center Groningen
Regeneron Pharmaceuticals
Big Ten Cancer Research Consortium
Inhibrx Biosciences, Inc
Mayo Clinic
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
BeiGene
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Avistone Biotechnology Co., Ltd.
Bristol-Myers Squibb
Fundación GECP
Checkpoint Therapeutics, Inc.